Universal Ibogaine Stock Net Income
| IBOGF Stock | USD 0.01 0 11.11% |
As of the 19th of February, Universal Ibogaine has the Risk Adjusted Performance of 0.1194, coefficient of variation of 698.37, and Semi Deviation of 19.15. Universal Ibogaine technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Universal Ibogaine variance and the relationship between the treynor ratio and expected short fall to decide if Universal Ibogaine is priced more or less accurately, providing market reflects its prevalent price of 0.0088 per share. As Universal Ibogaine appears to be a penny stock we also recommend to double-check its total risk alpha numbers.
Universal Ibogaine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Universal Ibogaine's valuation are provided below:Universal Ibogaine does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Universal |
Universal Ibogaine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Universal Ibogaine's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Universal Ibogaine.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Universal Ibogaine on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Universal Ibogaine or generate 0.0% return on investment in Universal Ibogaine over 90 days. Universal Ibogaine is related to or competes with Ayala Pharmaceuticals. Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada More
Universal Ibogaine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Universal Ibogaine's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Universal Ibogaine upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 23.73 | |||
| Information Ratio | 0.1409 | |||
| Maximum Drawdown | 113.91 | |||
| Value At Risk | (31.03) | |||
| Potential Upside | 52.5 |
Universal Ibogaine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Universal Ibogaine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Universal Ibogaine's standard deviation. In reality, there are many statistical measures that can use Universal Ibogaine historical prices to predict the future Universal Ibogaine's volatility.| Risk Adjusted Performance | 0.1194 | |||
| Jensen Alpha | 3.8 | |||
| Total Risk Alpha | 2.07 | |||
| Sortino Ratio | 0.1682 | |||
| Treynor Ratio | 0.8977 |
Universal Ibogaine February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1194 | |||
| Market Risk Adjusted Performance | 0.9077 | |||
| Mean Deviation | 20.19 | |||
| Semi Deviation | 19.15 | |||
| Downside Deviation | 23.73 | |||
| Coefficient Of Variation | 698.37 | |||
| Standard Deviation | 28.31 | |||
| Variance | 801.73 | |||
| Information Ratio | 0.1409 | |||
| Jensen Alpha | 3.8 | |||
| Total Risk Alpha | 2.07 | |||
| Sortino Ratio | 0.1682 | |||
| Treynor Ratio | 0.8977 | |||
| Maximum Drawdown | 113.91 | |||
| Value At Risk | (31.03) | |||
| Potential Upside | 52.5 | |||
| Downside Variance | 562.94 | |||
| Semi Variance | 366.56 | |||
| Expected Short fall | (26.93) | |||
| Skewness | 1.29 | |||
| Kurtosis | 3.69 |
Universal Ibogaine Backtested Returns
Universal Ibogaine is out of control given 3 months investment horizon. Universal Ibogaine owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.14, which indicates the firm had a 0.14 % return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 4.03% are justified by taking the suggested risk. Use Universal Ibogaine Coefficient Of Variation of 698.37, risk adjusted performance of 0.1194, and Semi Deviation of 19.15 to evaluate company specific risk that cannot be diversified away. Universal Ibogaine holds a performance score of 10 on a scale of zero to a hundred. The entity has a beta of 4.51, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Universal Ibogaine will likely underperform. Use Universal Ibogaine jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Universal Ibogaine.
Auto-correlation | -0.58 |
Good reverse predictability
Universal Ibogaine has good reverse predictability. Overlapping area represents the amount of predictability between Universal Ibogaine time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Universal Ibogaine price movement. The serial correlation of -0.58 indicates that roughly 58.0% of current Universal Ibogaine price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.58 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Universal Ibogaine reported net income of (10.5 Million). This is 103.08% lower than that of the Healthcare sector and 114.98% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.84% higher than that of the company.
Universal Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Universal Ibogaine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Universal Ibogaine could also be used in its relative valuation, which is a method of valuing Universal Ibogaine by comparing valuation metrics of similar companies.Universal Ibogaine is currently under evaluation in net income category among its peers.
Universal Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (4.29) % | |||
| Current Valuation | 4.25 M | |||
| Shares Outstanding | 191.14 M | |||
| Shares Owned By Insiders | 9.51 % | |||
| Price To Book | 1.25 X | |||
| Price To Sales | 3.67 X | |||
| Revenue | 1.07 M | |||
| Gross Profit | 497.15 K | |||
| EBITDA | (10.16 M) | |||
| Net Income | (10.5 M) | |||
| Cash And Equivalents | 1.95 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.74 M | |||
| Debt To Equity | 0.24 % | |||
| Current Ratio | 2.40 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (4.33 M) | |||
| Earnings Per Share | (0.02) X | |||
| Market Capitalization | 2.84 M | |||
| Total Asset | 6.32 M | |||
| Z Score | -2.7 | |||
| Net Asset | 6.32 M |
About Universal Ibogaine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Universal Ibogaine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Universal Ibogaine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Universal Ibogaine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Universal Pink Sheet
Universal Ibogaine financial ratios help investors to determine whether Universal Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Universal with respect to the benefits of owning Universal Ibogaine security.